Ann: Trading Halt, page-713

I am counting on the fact that the profits will not come from just having a covid 19 specific cure. Profits from any drug just for this will not be great anyway. Not when a vaccine is on its way as well. What attracted me to the company is managing inflammation is to health what insulin was for diabetes. Organ transplants,heart disease, autoimmune diseases the role inflammation played is endless. It will be attractive to a major player out there for its range of possibilities for many applications . Managing a cytokine storm utilises that anti inflammatory capacity. I have no idea what will happen short term.It does have big company competition given the huge stakes and race in this area. . It will require a partnership and or major investor to manage the next level. I buy incrementally with biotech stock building to successful phase three trials. It is always a risk.